Literature DB >> 32046870

Siglec-10 expression is up-regulated in activated human CD4+ T cells.

E Bandala-Sanchez1, N G Bediaga1, G Naselli1, A M Neale1, L C Harrison2.   

Abstract

Most sialic acid-binding immunoglobulin-like lectins (Siglecs) suppress immune cell function but are expressed at low levels on human T cells. We found that soluble CD52 inhibited T cell signalling by ligating Siglec-10, but the presence of Siglec-10 on human T cells has been questioned. To address this concern, we examined the expression of Siglec-10 at the RNA and protein level in human CD4+ T cells. Analysis by RNAseq, qPCR and flow cytometry demonstrated that, in contrast to other Siglecs, after activation of CD4+ T cells Siglec-10 was selectively upregulated in a subset of cells also high for CD52 expression. This observation is consistent with a homeostatic role for Siglec-10 in human CD4+ T cells.
Copyright © 2020 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activation; CD4(+) T cell; CD52; Protein; RNA; Siglec-10

Year:  2020        PMID: 32046870     DOI: 10.1016/j.humimm.2020.01.009

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  Unveiling Molecular Recognition of Sialoglycans by Human Siglec-10.

Authors:  Rosa Ester Forgione; Cristina Di Carluccio; Juan Guzmán-Caldentey; Rosa Gaglione; Filomena Battista; Fabrizio Chiodo; Yoshiyuki Manabe; Angela Arciello; Pompea Del Vecchio; Koichi Fukase; Antonio Molinaro; Sonsoles Martín-Santamaría; Paul R Crocker; Roberta Marchetti; Alba Silipo
Journal:  iScience       Date:  2020-06-02

Review 2.  The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.

Authors:  Simona Rolla; Alessandro Maglione; Stefania Federica De Mercanti; Marinella Clerico
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

Review 3.  Siglec Signaling in the Tumor Microenvironment.

Authors:  Eline J H van Houtum; Christian Büll; Lenneke A M Cornelissen; Gosse J Adema
Journal:  Front Immunol       Date:  2021-12-13       Impact factor: 7.561

4.  Improvement of Lipoplexes With a Sialic Acid Mimetic to Target the C1858T PTPN22 Variant for Immunotherapy in Endocrine Autoimmunity.

Authors:  Andrea Arena; Eugenia Belcastro; Francesca Ceccacci; Stefania Petrini; Libenzio Adrian Conti; Olivia Pagliarosi; Ezio Giorda; Simona Sennato; Riccardo Schiaffini; Peng Wang; James C Paulson; Giovanna Mancini; Alessandra Fierabracci
Journal:  Front Immunol       Date:  2022-03-09       Impact factor: 7.561

5.  Multiple datasets to explore the molecular mechanism of sepsis.

Authors:  Shuang Lin; Bin Luo; Junqi Ma
Journal:  BMC Genom Data       Date:  2022-08-15

6.  CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.

Authors:  Yuichi Ozawa; Yuhei Harutani; Jun Oyanagi; Hiroaki Akamatsu; Eriko Murakami; Ryota Shibaki; Atsushi Hayata; Takeya Sugimoto; Masanori Tanaka; Toshiaki Takakura; Katsuyuki Furuta; Yuka Okuda; Kouichi Sato; Shunsuke Teraoka; Hiroki Ueda; Nahomi Tokudome; Yuka Kitamura; Junya Fukuoka; Masanori Nakanishi; Yasuhiro Koh; Nobuyuki Yamamoto
Journal:  Cancer Sci       Date:  2020-11-27       Impact factor: 6.518

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.